Tag: Resverlogix

Resverlogix Supports Epigenetics Satellite Symposium and Provides Oral Presentation on Apabetalone at the European Society of Cardiology Congress 2018 in Munich

CALGARY, Alberta, Aug. 22, 2018 (GLOBE NEWSWIRE) — Resverlogix Corp. (“Resverlogix” or the “Company”) (TSX:RVX) today announced it is supporting a satellite symposium on August 25th, 2018, at the European Society of Cardiology Congress 2018 in Munich, Germany, titled: LDL-c: Done Deal, Next Epigenetics? Satellite Symposium Agenda 15:30 – 15:35 (local […]

Resverlogix Announces Seventh Positive Recommendation From The Data Safety Monitoring Board For Phase 3 Study of Apabetalone

CALGARY, Alberta,, Aug. 07, 2018 (GLOBE NEWSWIRE) — Resverlogix Corp. (“Resverlogix” or the “Company”) (TSX:RVX) today announced  that the independent Data and Safety Monitoring Board (DSMB) for the Company’s Phase 3 BETonMACE trial in high-risk cardiovascular disease (CVD) patients has completed a seventh planned safety review and recommended that the […]

Resverlogix (RVX.TO) Randomizes First Patient In Taiwan/China Portion Of The Phase III BETonMACE Clinical Trial

CALGARY, July 10, 2017 /PRNewswire/ – Resverlogix Corp. (“Resverlogix” or the “Company”) (TSX:RVX) today announced  that the first patient has been randomized in Taiwan in the Phase 3 BETonMACE clinical trial with lead drug apabetalone intended for high-risk patients with cardiovascular disease (“CVD”) and type 2 diabetes mellitus (“DM”). On July 8, 2015, Resverlogix and […]